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Abstract 17 
 18 
p97 is a ‘segregase’ that plays a key role in numerous ubiquitin-dependent 19 
pathways, such as ER-associated degradation (ERAD). It has been hypothesized 20 
that p97 extracts proteins from membranes or macromolecular complexes to 21 
enable their proteasomal degradation; however, the complex nature of p97 22 
substrates has made it difficult to directly observe the fundamental basis for this 23 
activity. To address this issue, we developed a soluble p97 substrate—Ub-GFP 24 
modified with K48-linked ubiquitin chains—for in vitro p97 activity assays. We 25 
demonstrate for the first time that wild type p97 can unfold proteins and that this 26 
activity is dependent on the p97 adaptor NPLOC4-UFD1L, ATP hydrolysis, and 27 
substrate ubiquitination, with branched chains providing maximal stimulation. 28 
Furthermore, we show that a p97 mutant that causes inclusion body myopathy, 29 
Paget’s Disease of bone, and frontotemporal dementia (IBMPFD) in humans 30 
unfolds substrate faster, suggesting that excess activity may underlie 31 
pathogenesis. This work overcomes a significant barrier in the study of p97 and 32 
will allow the future dissection of p97 mechanism at a level of detail previously 33 
unattainable. 34 
 35 
Introduction 36 
 37 
The AAA ATPase p97, also called valosin containing protein (VCP) or Cdc48 in 38 
yeast, is integral to a wide array of processes in the cell (1, 2). Its role in ER-39 
associated degradation (ERAD) is the most well-studied, where it functions to 40 
pull misfolded proteins from the ER membrane so they can be degraded by the 41 
proteasome (3). Other degradative pathways with substrates embedded in large 42 
structures, such as ribosome associated degradation (RAD) and mitochondrial 43 
associated degradation (MAD), also rely on the activity of p97 (4–6). 44 
Furthermore, p97 is involved in non-degradative pathways like Golgi and nuclear 45 
envelope reassembly after mitosis and endosomal trafficking (7, 8). The common 46 
mechanism that underlies all of these cellular jobs is presumed to be the 47 
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extraction and unfolding of ubiquitylated proteins by p97 (9, 10).  Its homology to 48 
other AAA ATPases that have demonstrated unfolding activities, such as the 49 
proteasome 19S regulatory particle (11, 12), ClpA (13), and VAT (14, 15), further 50 
support the model of p97 as an unfoldase. While p97 has been shown to extract 51 
proteins from membranes and DNA, its ability to unfold a protein has not been 52 
explicitly demonstrated.  Because of this considerable gap in our knowledge, the 53 
biochemical activity that underlies p97’s myriad functions remains a mystery.  54 
 55 
Despite our poor molecular understanding of exactly what p97 does and how it 56 
does it, structural studies and indirect assays have provided some insight into 57 
p97 activity. p97 is a homohexamer, with each protomer comprising an N-58 
domain, two ATPase domains (D1 and D2) stacked one upon the other, and an 59 
unstructured C-terminal tail (16–18). Whereas both ATPase domains are 60 
functional, it is thought that hydrolysis of ATP in D2 is the main driver of 61 
mechanical force and ATP binding in D1 promotes hexamer formation (19–25). 62 
The conformations of the two ATPase domains and the N-domain with respect to 63 
one another are highly cooperative and dependent upon nucleotide binding and 64 
hydrolysis (17, 18, 20, 22, 26–32). Recent high-resolution structural studies show 65 
movement of D2 relative to N-D1 upon ATP binding in D2, while the N domains 66 
move from a coplanar to an axial position with respect to D1 upon ATP binding to 67 
D1 (18). It is unclear how these conformational changes translate to mechanical 68 
force for remodeling protein substrates. Homologues like ClpA function by 69 
threading polypeptides through the central pore (33), and though p97 lacks the 70 
requisite hydrophobic pore residues in D1, other pore residues interact with and 71 
are key to the processing of substrates (19, 34). However, structural studies 72 
imply that the central pore of p97 may be too narrow to accommodate a 73 
polypeptide (16, 18). Other proposed mechanisms include unfolding by D2 74 
through the arginine “denaturation collar” and unfolding outside of the pore by the 75 
movement of the N-domains similar to what has been proposed for NSF (34, 35). 76 
Resolution of the key question of how p97 works has been stymied by the lack of 77 
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a direct assay to measure the core biochemical activity underlying its segregase 78 
function. 79 
 80 
In performing its biological functions, p97 does not act alone but instead 81 
associates with a set of adaptor proteins that act to recruit or modify substrates 82 
(36). Many of the adaptors contain ubiquitin-binding domains or can add or 83 
remove ubiquitin modifications, thereby linking p97 to ubiquitin signaling (36, 37). 84 
Some adaptors also modulate p97 ATPase activity (38–40). Whereas a few 85 
adaptors have been linked to specific pathways or substrates (41, 8, 42–44), the 86 
functions of others remain unknown (36, 37). The best characterized p97 adaptor 87 
is the heterodimer of NPLOC4/Npl4 and UFD1L/Ufd1 (UN), which recruits 88 
substrates in ERAD and other proteasome-dependent degradative processes 89 
(45–47). NPLOC4 and UFD1L each bind ubiquitin chains, with UFD1L showing 90 
specificity for K48-linked chains (25, 48, 49). They interact with p97 at separate 91 
sites to form a complex with the stoichiometry of one UN heterodimer per p97 92 
hexamer (39, 46, 50–52).  93 
 94 
A significant incentive to gaining a deeper understanding of p97 mechanism of 95 
action is the deep connection between this protein and human disease, and 96 
possibly cancer therapy. Human p97 is mutated in the inherited, autosomal-97 
dominant multisystem proteinopathy known as IBMPFD (53, 54). In addition, a 98 
small fraction of patients with inherited Amyotrophic Lateral Sclerosis (ALS/Lou 99 
Gehrig’s Disease) also carry mutations in p97 that overlap with those seen in 100 
IBMPFD patients (54, 55). However, the mechanism of pathogenesis is not 101 
understood in either case. It has been suggested at various times that 102 
pathogenesis arises from a failure of autophagy, endosomal sorting, clearance of 103 
leaky lysosomes, mitochondrial homeostasis, or mTOR regulation (56, 57, 8, 58–104 
61). Regardless of the cellular target, the molecular-level defect remains 105 
obscure. It has been suggested that failure of mutant p97 to bind UBXN6/UBXD1 106 
is key (8), but IBMPFD mutants also show increased binding of UN (62). The 107 
mutations that cause IBMPFD all fall within the N-D1 domain interface and affect 108 
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the relative orientation of these domains (63–66). Moreover, the mutations cause 109 
elevated ATP hydrolysis (20, 63–65, 67), but it has been suggested that this is an 110 
indirect consequence of a decoupling of substrate binding from 111 
mechanochemical transduction in the D2 domain (54, 68). Because p97 is a 112 
hexamer, it has been unclear how to interpret the autosomal dominant nature of 113 
IBMPFD. Is this truly due to enhanced activity, or do the mutations actually cause 114 
reduction-of-function through a dominant-negative mechanism, with mutant 115 
protomers poisoning mixed hexamers? Studies in Drosophila support the idea 116 
that the pathogenesis of IBMPFD mutations stems from elevated p97 activity, 117 
resulting in increased processing of TDP-43 (69) and mitofusin (61). As of yet 118 
there remains no biochemical assay that measures p97’s presumed core function 119 
of protein unfolding that would enable a direct test of this hypothesis in a defined 120 
system. 121 
 122 
The nature of the majority of known p97 substrates—unstable, scarce, modified 123 
by ubiquitin, and not readily divorced from their contexts—presents challenges 124 
for studying the enzymatic activity of p97 in a systematic manner. A major barrier 125 
to progress has been the absence of a simple, rapid, quantitative assay using 126 
defined components, that can be employed to dissect in detail the mechanism of 127 
action of p97. To address this obstacle, we have developed a soluble, 128 
monomeric p97 substrate. Our substrate is based on a non-cleavable ubiquitin 129 
fusion protein, UbG76VGFP, which is targeted for proteolysis by the Ub fusion 130 
degradation (UFD) pathway (70). Normally, ubiquitin fusions are co-131 
translationally cleaved by a deubiquitinating enzyme to remove the ubiquitin (71). 132 
However, if the C-terminal glycine is mutated, processing is blocked and the 133 
fusion is rapidly degraded. Previous studies have demonstrated that the 134 
degradation of these non-cleavable Ub fusion proteins, including UbG76VGFP, is 135 
dependent upon p97•UN in human, Drosophila, and yeast cells (19, 47, 70, 72). 136 
We show that p97 can unfold UbG76VGFP modified with a K48-linked polyUb 137 
chain and that this reaction is dependent upon the nature of the Ub chain, UN, 138 
and p97 ATPase activity in D2. Our system provides the first direct 139 
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/129528doi: bioRxiv preprint first posted online Apr. 21, 2017; 
6 
 
demonstration of a p97 unfoldase activity that depends on predicted 140 
physiological requirements and will be an invaluable tool for further study of p97 141 
mechanism. 142 
 143 
Results 144 
 145 
Substrate and assay design 146 
 147 
We chose to pursue the UFD pathway substrate UbG76VGFP because it is rapidly 148 
degraded in a p97-dependent manner in yeast, Drosophila, and human cells (19) 149 
and is a well-behaved protein whose folding state can be easily monitored by 150 
fluorescence. Since p97 substrates are often polyubiquitylated, and p97•UN 151 
binds polyubiquitin (25), we reasoned that UbG76VGFP would need to be 152 
polyubiquitylated to be recognized. To efficiently ubiquitylate it, we developed a 153 
chimera of the RING domain from the E3 ubiquitin ligase gp78 and the E2 154 
enzyme Ube2g2. Prior studies have shown that these enzymes catalyze 155 
formation of K48-linked ubiquitin chains (25). Notably, these two enzymes 156 
function upstream of p97 in ERAD, attesting to the physiological relevance of 157 
using these enzymes to generate a p97 substrate for our assay (73, 74). As 158 
compared to Ube2g2 alone or unfused Ube2g2 with added gp78RING (Fig. 159 
S1A), the gp78RING-Ube2g2 chimera produced unanchored polyUb chains with 160 
very high efficiency (Fig. S1B). 161 
 162 
Using this tool, we employed various strategies to produce three types of 163 
potential p97 substrates. To simplify notation, linearly fused proteins are shown 164 
by dashes, and the length of the K48-linked Ub chain attached to a particular Ub 165 
is shown with a superscript preceding the initiator Ub. First, we aimed to create a 166 
substrate with a short Ub chain of defined length. Although the minimal 167 
requirement for recognition of ubiquitylated proteins by p97 is not known, the 168 
minimum Ub chain length for recognition by the proteasome is four (75). 169 
Therefore, we enzymatically ligated Ub3, in which the ubiquitins were joined via 170 
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K48 linkages and the distal ubiquitin carried a K48R mutation, onto the linearly 171 
fused Ub to form pure Ub3Ub-GFP (Fig.1A) (76, 77). Second, to create a 172 
substrate with longer polyubiquitin chains, we built K48-linked chains directly 173 
onto the linearly fused Ub (Fig. 1B). Finally, to produce substrate with branched 174 
Ub chains, we built Ub chains on a base substrate containing two or more 175 
linearly-fused Ub (Ub-Ub-GFP or Ub-Ub-Ub-GFP) (Fig. 1C). Heterogeneous 176 
substrates were fractionated by size exclusion chromatography to enrich for 177 
different chain lengths (Fig. 1D). 178 
 179 
One concern we had was the potential for GFP to refold after being processed by 180 
p97, leaving the assay without an observable endpoint. To address this, we 181 
added an ATPase mutant of the chaperonin GroEL. The GroEL D87K ‘trap’ 182 
retains the ability to bind unfolded proteins but can no longer release those 183 
proteins (78). This dead-end complex sequesters unfolded GFP, preventing it 184 
from refolding, and has been used previously to provide assay endpoints for 185 
other unfolding machines (13).  186 
  187 
GFP is unfolded by p97 in an Ub- and UN-dependent manner 188 
 189 
To explore the unfolding potential of p97, we first compared a set of Ub-GFP 190 
substrates bearing K48-linked ubiquitin chains of varying lengths (Fig. 2A). When 191 
mixed with p97, UN, and GroEL (Fig. S2), Ub-GFP and Ub3Ub-GFP showed no 192 
appreciable loss of GFP fluorescence (Fig. 2B). However, Ub-GFP with both 193 
“medium” (>4 Ub, UbMUb-GFP) and “long” (>12 Ub, UbLUb-GFP) ubiquitin chains 194 
showed a modest decrease in fluorescence over time (~30%, Fig. 2B). Whereas 195 
UbLUb-GFP did show improved unfolding relative to UbMUb-GFP, the difference 196 
was quite small (~5% signal loss). 197 
 198 
We examined further the requirements for p97-dependent unfolding using UbLUb-199 
GFP, since this substrate gave the largest signal. When incubated with only p97 200 
or p97 and GroEL, no unfolding was observed (Fig. 2C). A similar result was 201 
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/129528doi: bioRxiv preprint first posted online Apr. 21, 2017; 
8 
 
obtained when UN was replaced with NSFL1C/p47 or UBXN7/UBXD7, p97 202 
adaptors involved in Golgi reassembly after mitosis (41) and regulation of cullin-203 
RING Ub ligases (37, 43, 79), respectively, despite both of these adaptors 204 
binding to p97 and substrate (Fig. S3). Therefore, UN is required for p97-205 
catalyzed unfolding, and it cannot be replaced by other adaptors. Additionally, 206 
GroEL was essential to provide an endpoint for the assay. Fluorescence loss 207 
was amplified by the addition of GroEL (Fig. 2C), indicating GFP was able to 208 
refold to some degree after processing by p97•UN. However, GroEL did not 209 
unfold substrate on its own (Fig. 2C), and immunoprecipitation of GroEL showed 210 
that p97•UN was required for GroEL interaction with substrate (Fig. 2D). 211 
Unfolding of substrate by p97 was also highly temperature dependent, with the 212 
rate and extent of unfolding increasing between 22-42 ˚C (Fig. S4). 213 
 214 
We found it curious that ≤40% of the fluorescence signal of UbLUb-GFP was 215 
typically lost in our unfolding assays even though all components of the system 216 
were at or very near saturation (Fig. S5), suggesting that there was another 217 
factor influencing substrate competence that remained to be discovered. Three 218 
Ub binding sites with different chain linkage preferences are available on p97•UN 219 
(25). Therefore, we tested whether substrates carrying branched Ub chains 220 
would be more effectively unfolded, because a branch would enable two 221 
separate ubiquitin chains to be elaborated from a single attachment point (in this 222 
case, Met1 of GFP). As a proxy for Ub chains with branched linkages, we 223 
expressed Ub-GFP fused to one or more additional ubiquitins in tandem and 224 
used these proteins as substrates for subsequent enzymatic polyubiquitylation 225 
(Fig. 3A). Interestingly, a substrate in which K48-linked polyubiquitin chains were 226 
polymerized on Ub-Ub-GFP (UbMUb-UbMUb-GFP) showed significant improvement 227 
in unfolding by p97 as compared to UbMUb-GFP (Fig. 3B) despite the latter having 228 
a greater amount of ubiquitin conjugation as judged by mobility upon SDS-PAGE 229 
(Fig. 3A, lanes 1 and 2). Neither further extension of the chains to form UbLUb-230 
UbLUb-GFP nor use of a triubiquitin fusion significantly increased the rate or 231 
extent of unfolding (Fig. 3B). Although we cannot directly visualize ubiquitin 232 
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chains branching from each ubiquitin in the Ub-Ub-GFP fusion protein, reactions 233 
run with Ub-K48R indicate that both Ub moieties were efficiently conjugated with 234 
ubiquitin under our reaction conditions (Fig. S6). Incidentally, this same reaction 235 
confirms the linkage specificity of our Ube2g2–gp78 E2–E3 chimera. Taken 236 
together, our data suggest that the physical arrangement of the Ub chains is 237 
important for unfolding by p97•UN, with the enzyme preferring substrates with at 238 
least one branch point that enables nucleation of more than one chain of K48-239 
linked ubiquitins. 240 
 241 
Substrate unfolding is dependent upon ATP hydrolysis and stimulates p97 242 
ATPase activity  243 
 244 
Next we examined the energy-dependence of p97-catalyzed unfolding. UbLUb-245 
UbLUb-GFP was not unfolded by p97 in the absence of nucleotide, and ADP or 246 
the nonhydrolyzable ATP analog ATPγS could not substitute for ATP (Fig. 4A). 247 
Two p97 ATPase inhibitors, the allosteric inhibitor NMS-873 (80) and the D2-248 
specific, ATP-competitive inhibitor CB-5083 (81), also prevented ATP-dependent 249 
substrate processing (Fig. 4A). p97 with a D1 domain Walker B motif mutation 250 
(p97-E305Q) that blocks nucleotide hydrolysis but not binding exhibited only mild 251 
defects in substrate unfolding. By contrast, the same mutation in D2 (p97-252 
E578Q) completely abolished unfoldase activity (Fig. 4B; Table 1). Together, 253 
these data demonstrate that ATP hydrolysis in D2 powers the unfolding of 254 
substrate by p97•UN. 255 
 256 
Some adaptors modulate p97 ATPase activity (38), so we examined the effects 257 
of substrate processing on the hydrolysis of ATP by p97 and p97•UN. Addition of 258 
long unanchored K48-linked ubiquitin chains (UbLUb), Ub-GFP, Ub3Ub-GFP or 259 
UbLUb-UbLUb-GFP did not alter the ATPase activity of p97 (Fig. S7A). Whereas 260 
UN did not significantly affect the ATPase activity of p97, the further addition of 261 
UbLUb-UbLUb-GFP stimulated ATP hydrolysis by ~4-fold, whereas Ub-GFP and 262 
Ub3Ub-GFP had no effect (Fig. 4C). The latter result is consistent with the inability 263 
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of p97•UN to unfold Ub-GFP or Ub3Ub-GFP. Neither NSFL1C nor UBXN7 264 
supported substrate-triggered acceleration of p97 ATP hydrolysis (Fig. S7B). 265 
Long, unanchored Ub chains also stimulated p97 ATPase activity to a similar 266 
degree as UbLUb-UbLUb-GFP, suggesting that p97 interaction with Ub chains and 267 
not the GFP substrate itself was both necessary and sufficient for the observed 268 
acceleration. In agreement with the unfolding results, the residual ATPase 269 
activity of p97-E578Q was unaffected by substrate plus UN (Fig. 4D). However, 270 
p97-E305Q, which was able to unfold substrate, was also not stimulated by 271 
substrate, even showing a slight decrease in ATPase activity (Fig. 4D). The 272 
E305Q mutant also showed higher basal ATPase activity than WT, as has been 273 
seen before in steady-state experiments (20). These results suggest that there is 274 
a high degree of crosstalk between ATPase activity in D1 and D2, and whereas 275 
ATP hydrolysis in D2 is the driving force for unfolding, D1 activity is also needed 276 
for substrate-induced ATPase acceleration. 277 
 278 
UN recruits substrate to p97 279 
 280 
The tight correlation between the competence of a substrate to be unfolded and 281 
its ability to accelerate ATP hydrolysis suggests that binding of substrate to p97 282 
may stimulate ATPase activity, leading to substrate unfolding. To further probe 283 
this hypothesis, we evaluated binding of substrate to p97. Immunoprecipitation of 284 
p97 showed that it bound UbLUb-UbLUb-GFP substrate in the presence but not in 285 
the absence of UN (Fig. 5A, lanes 4 and 5). Reciprocal immunoprecipitation of 286 
GFP confirmed that substrate bound UN in the absence of p97 but did not bind 287 
p97 in the absence of UN (Fig. 5B). Furthermore, the interaction between p97 288 
and UN appeared to be stabilized by substrate binding (Fig. 5A, lanes 3 and 5). 289 
We also analyzed substrate dependence of GroEL association with p97, but 290 
observed high background binding to our beads even in the absence of antibody 291 
(lane 1). The binding signal was increased in lanes 6 and 7, but this could be due 292 
to p97, which in our experience is prone to exhibit non-specific binding.  293 
 294 
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Whereas the unfolding of substrate was highly dependent on ATP hydrolysis, 295 
substrate interaction with p97 was not. Immunoprecipitation of FLAG-UbLUb-FLAG-296 
UbLUb-GFP pulled down equal amounts of p97 in the absence of added 297 
nucleotide and in the presence of ATP, ATPγS, ATP plus NMS-873, and ATP 298 
plus CB-5083 (Fig. 5C). Therefore, p97 does not have to be actively remodeling 299 
substrate in order to effectively form a tight complex. Loss of binding of p97, but 300 
not UN, was seen only with added ADP, which could be due to the large 301 
conformational changes observed for p97 in its ADP-bound state (18) (Fig. 5C). 302 
These results are consistent with previous studies on Ub chain association with 303 
p97 and p97•UN (48, 82). 304 
 305 
IBMPFD mutant p97-A232E has enhanced unfoldase activity 306 
 307 
The autosomal dominant human syndrome IBMPFD is caused by mutations that 308 
cluster at the interface of the N and D1 domains of p97. Of the different IBMPFD 309 
mutations that have been identified in p97, A232E exhibits the most severe 310 
phenotype in terms of age of onset and penetrance. In addition, p97-A232E 311 
consistently shows higher basal D2 ATPase rates than wild-type enzyme (20, 63, 312 
65). The availability of an assay that directly measures ATP-dependent unfolding 313 
by p97 allowed us to distinguish between two alternative interpretations of the 314 
significance of the enhanced ATPase activity of the A232E mutant protein. On 315 
the one hand, the enhanced activity may reflect a true gain-of-function wherein 316 
p97-A232E is either a more powerful or faster motor. On the other hand, ATPase 317 
activity may increase because of decoupling of the D2 “motor” from the substrate 318 
“load”, analogous to pushing in the clutch when an engine is revving in low gear. 319 
If the former is more accurate we would expect to see increased unfolding by the 320 
mutant protein. Conversely, if the latter is correct, we would expect to see 321 
reduced unfolding. The result of this experiment was unambiguous: p97-A232E 322 
exhibited accelerated unfolding of GFP under the single-turnover conditions used 323 
in the assay (Fig. 6A, Table 1). This effect is reproducible, because in two 324 
independent sets of preparations, p97-A232E displayed faster unfolding than WT 325 
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p97 (Fig. 6A and Fig. 6C). The substrate-induced ATPase acceleration observed 326 
for WT p97 was also observed with p97-A232E (Fig. 6B). The mutant protein 327 
displays an increased basal rate of ATP hydrolysis and a higher rate in the 328 
presence of substrate compared to WT. 329 
 330 
We identified a reversible, ATP-competitive p97 ATPase inhibitor that was 331 
recently perfected to yield the clinical candidate CB-5083 (81), which is in human 332 
phase 1 clinical trials for treatment of cancer. If the basis of IBMPFD pathology is 333 
due to enhanced unfoldase activity of p97, we reasoned that CB-5083 could 334 
potentially be explored as a therapy for IBMPFD. To test the feasibility of this 335 
idea, we performed unfolding reactions with p97-A232E at several different 336 
concentrations of CB-5083. Remarkably, when added at 37.5 nM, or 1 molecule 337 
per 2 p97 hexamers, CB-5083 normalized the unfolding rate of p97-A232E to 338 
match that of WT (Fig. 6C).  339 
 340 
Discussion 341 
 342 
P97/VCP is implicated in a broad range of cellular processes including 343 
membrane fusion, protein trafficking, and ubiquitin-dependent proteolysis (1). It is 344 
thought that the core biochemical activity of p97 that enables its diverse 345 
biological functions is its ability to act as a ‘segregase’ that segregates 346 
polypeptides from binding partners in multisubunit complexes, or from large 347 
macromolecular structures including ribosomes, membranes, or chromatin. 348 
Although the mechanism by which p97 exerts segregase activity is not known, 349 
the most economical hypothesis is that it grabs onto the polypeptide to be 350 
segregated and commences to unfold it. However, despite the appeal of this 351 
unifying hypothesis, the ability of wild type p97 to harvest the energy of ATP 352 
hydrolysis to unfold a polypeptide has never been directly demonstrated. We 353 
show here for the first time, and in a well-defined system, that wild type p97 can 354 
at least partially unfold a protein. In contrast to prior studies that employed a 355 
doubly-mutated p97 acting upon an unmodified protein in the absence of any 356 
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adaptor (83, 84), the unfolding we observe exhibits dependencies predicted from 357 
prior genetic and biochemical studies of p97, including dependence on ATP 358 
hydrolysis by the D2 ATPase domain of p97, the heterodimeric adaptor 359 
NPLOC4•UFD1L, and conjugation of an ubiquitin chain to the substrate that is 360 
unfolded (1, 24, 25).  361 
 362 
Despite the close alignment of in vitro dependencies reported here with known in 363 
vivo requirements for p97 action, there are two caveats worth noting. First, we do 364 
not know whether the loss of GFP fluorescence is due to complete unfolding or 365 
local unfolding. Second, our Ub-GFP model substrate is not a native substrate of 366 
p97. However, p97 activity in the UFD pathway is absolutely required for its 367 
degradation in vivo in yeast, Drosophila, and human cells (19, 47, 70, 72), and 368 
the E2–E3 chimera employed to ubiquitylate Ub-GFP was derived from enzymes 369 
that function directly upstream of p97 in the ERAD pathway (73). Thus, we 370 
believe the reaction reported here represents the essence of p97’s biochemical 371 
activity that underlies its physiological functions. 372 
 373 
Processing of our Ub-GFP substrate by p97 is dependent on the conjugation of 374 
multiple ubiquitins connected by K48 linkages, which is consistent with reports of 375 
K48-linked Ub chain binding by p97 and UFD1L and linkage-nonspecific chain 376 
binding by NPLOC4 (25, 48, 49, 82). One of our most interesting findings is that 377 
we observed enhanced substrate unfolding when the substrate contained a 378 
branch point enabling the formation of multiple K48-linked ubiquitin chains. Our 379 
substrate contains a branch at the base of the ubiquitin conjugate, which allows 380 
for two K48-linked chains to be built on a single site of substrate modification. 381 
Because there are multiple Ub binding sites on the p97•UN complex, the 382 
branched chain on our UbLUb-UbLUb-GFP substrate may retard, via enhanced 383 
avidity, its dissociation prior to unfolding. Branched Ub chains can enhance 384 
substrate degradation (85) and have been associated with p97 previously. 385 
Ubiquitin chains with K11 linkages are associated with multiple p97 adaptor 386 
proteins (37) and are implicated in ERAD (86).  Substrates modified with K11 and 387 
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K11-K48 branched chains associate with p97•UN and its Drosophila ortholog (87, 388 
88), and p97 binds K11-K48 branched chains better than either type of 389 
homotypic chain (85). Furthermore, both K29 and K48 linkages are formed on 390 
UFD pathway substrates in vivo and in vitro using purified UFD pathway 391 
enzymes (47, 89). Whereas our data with linear ubiquitin fusions suggest 392 
branched and/or multiple ubiquitin chains may be important for interaction of 393 
substrates with p97•UN, further work with physiological linkages in vitro and in 394 
vivo is needed to determine the exact requirements for ubquitylated p97 395 
substrates. 396 
 397 
The second requirement for p97-catalyzed unfolding is the heterodimeric adaptor 398 
UN. In agreement with prior work, UN bridges the interaction of substrates with 399 
p97 (25, 48). However, p97 also associates with other adaptor proteins, some of 400 
which (e.g. UBXN7) can co-bind with UN and others (e.g. NSFL1C) which bind in 401 
a mutually exclusive manner (36, 37, 46, 90, 91). Although there are examples of 402 
processes that require both UN and an additional adaptor (42, 92), in general it is 403 
unclear whether the different adaptors work in different pathways, or work 404 
sequentially, together, or in opposition to one another in the same pathway. 405 
Mutually exclusive adaptors like NSFL1C bind very differently from UN yet also 406 
promote protein segregation (41, 51, 93). However, neither NSFL1C nor UBXN7 407 
was able to replace UN in our unfolding assay, suggesting they promote 408 
substrate processing in a different way or work on different substrates. Our assay 409 
provides the first platform for further mechanistic exploration of the functional 410 
relationship between different adaptor proteins.  411 
 412 
The final requirement for unfolding of GFP is ATP hydrolysis by the D2 ATPase 413 
of p97. Our results are in direct contrast with a previous study which showed that 414 
p97-dependent unfolding is inhibited by ATP (94), but are consistent with 415 
overwhelming in vitro and in vivo data (1, 23, 25, 34). Our experiments with p97 416 
mutants and the D2-specific ATP-competitive inhibitor CB-5083 demonstrate the 417 
importance of D2 ATPase activity over that of D1, which confirms prior 418 
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observations (19–25). We observed very little effect of the D1 Walker B mutant 419 
on substrate processing, leaving the role of D1 ATPase activity in p97 function 420 
unclear (1). Not only is the ATPase activity key to substrate processing but we 421 
also observe its stimulation by Ub chain or substrate binding. This stimulation 422 
was abolished in the D1 Walker B mutant. Nevertheless, this mutant unfolded 423 
GFP at near-WT rates, suggesting that substrate stimulation of ATP hydrolysis 424 
might not be essential, at least for some substrates. ATPase acceleration in the 425 
presence of the cytoplasmic fragment of the ERAD substrate Sytl has been 426 
previously reported, but unlike the stimulation reported here, it was not 427 
dependent upon UN or ubiquitylation of the substrate (34), both of which are 428 
thought to be requirements for ERAD. p97 can interact both with a substrate and 429 
the Ub chain appended to the substrate (25, 95), suggesting that stimulation of 430 
p97 ATPase and perhaps substrate processing can be regulated through multiple 431 
binding interfaces. Though we are unable to draw any conclusions about the 432 
mechanism of unfolding by p97, studies on the archaebacterial homolog VAT 433 
support a model whereby substrate is translocated through the central channel 434 
(14, 15), suggesting that adaptor and substrate engagement must expand p97’s 435 
narrow pore (16, 18) to accommodate the threading of an unfolded polypeptide 436 
chain. 437 
 438 
Mutations in p97 cause the autosomal dominant human disease IBMPFD (53). 439 
Prior work has led to conflicting proposals regarding the underlying basis for 440 
pathogenesis in IBMPFD. On the one hand, some studies have emphasized a 441 
reduction in specific biological functions of the mutant p97, including its roles in 442 
endosomal trafficking, autophagy, and elimination of leaky lysosomes (56, 8, 60).  443 
Defects in these processes have been linked to reduced binding of mutant p97 to 444 
UBXD1 (8). On the other hand, IBMPFD mutant proteins hydrolyze ATP at a 445 
faster rate (20, 63–65). Whereas it has been speculated that the increase in ATP 446 
hydrolysis might be due to an uncoupling of substrate binding via the N domain 447 
to mechanochemical transduction in the D2 domain (54, 68), studies in 448 
Drosophila point to an increase in function for the mutant p97 (61, 67, 69). 449 
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Furthermore, the overexpression of WT p97 enhanced IBMPFD mutant 450 
phenotypes while inactivation of one copy of WT p97 suppressed mutant 451 
phenotypes, which is consistent with a gain-of-function mutation (96). The 452 
availability of a biochemical assay that directly measures substrate unfolding, 453 
which we propose is the core biochemical activity underlying p97’s myriad 454 
biological functions, allowed us to investigate this issue.  We focused on the 455 
mutant with the most severe disease phenotype, p97-A232E, and observed a 456 
modest but reproducible increase in the rate of substrate unfolding that was re-457 
normalized by addition of an ATP-competitive inhibitor, implying that the 458 
underlying defect in this disease may be due, in part, to a true gain-of-function 459 
rather than the prevailing loss-of-function hypothesis. Our results call to mind 460 
previous work to engineer Hsp104, in which point mutations greatly augmented 461 
its ATPase and unfoldase activity while altering intersubunit communication (97). 462 
It is interesting that the increased ATPase activity of p97-E305Q did not cause a 463 
similar increase in unfolding rate, suggesting that the rate of ATP hydrolysis in 464 
D2 does not by itself determine the rate of unfolding. Our experiments were 465 
carried out with pure WT and pure mutant p97, so it will be of interest to study 466 
populations of mixed hexamers of A232E and other IBMPFD mutants, to better 467 
recapitulate the situation that pertains in vivo. Whereas much clearly remains to 468 
be done to further investigate this gain-of-function model, if our proposal is 469 
correct it implies that the clinical-grade p97 inhibitor (81) that renormalized the 470 
activity of the mutant protein may be useful for therapy of IBMPFD and ALS 471 
cases that arise from mutation of p97. 472 
 473 
Methods 474 
 475 
Protein and expression purification  476 
A description of the construction, expression and purification of novel reagents is 477 
described below. A description of previously published proteins used in this study 478 
can be found in Table S1. 479 
 480 
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gp78RING-Ube2g2 chimera construction and purification 481 
A 72-residue sequence of the E3 ubiquitin protein ligase gp78/AMFR (residues 482 
322 to 393), containing the RING domain, was fused to the N-terminus of the 483 
ubiquitin-conjugating enzyme Ube2g2 with a linker sequence of GTGSH. cDNA 484 
encoding this fusion protein was inserted into the bacterial expression plasmid 485 
p28a-TEV vector to encode a polyHis-tagged protein. Protein was expressed in 486 
BL21(DE3) at 37 °C with 0.4 mM IPTG for 4 hours and was purified on Ni-NTA 487 
resin and a Superdex 75 column before being cleaved with TEV protease 488 
overnight at 4 °C. Cleaved protein was then bound to a MonoQ ion exchange 489 
column, eluted with a NaCl gradient (0.05 – 0.5 M), concentrated with centrifugal 490 
filter units, and flash frozen.  491 
 492 
UbG76VGFP fusion construction  493 
The coding sequence for UbG76VGFP in the EGFP-N1 vector (RDB# 1832) (19) 494 
was PCR amplified and inserted into pET28a using NdeI and NotI sites to 495 
produce His6-UbG76V-GFP (RDB# 3006). His6-UbG76V- UbG76V GFP (RDB# 3344) 496 
and His6-UbG76V-UbG76V-UbG76V -GFP (RDB# 3345) were created by ligating 497 
Ub2G76V and Ub3G76V, PCR amplified from a synthetic Ub4G76V sequence (RDB# 498 
2406), into His-UbG76V-GFP cut with NdeI and HindIII. For simplification, the 499 
G76V notation has been left out of subsequent mentions of these constructs. 500 
 501 
Ub3Ub-GFP synthesis and purification 502 
A plasmid for bacterial expression of Ub-K48R (RDB# 3348) was made from that 503 
of Ub (RDB# 2805) by site-directed mutagenesis, and the protein was expressed 504 
as previously described (76). Pure K48-linked Ub3 chains carrying a K48R 505 
mutation in the distal Ub were enzymatically synthesized and purified as 506 
described previously (76, 77). To form Ub3Ub-GFP, 0.5 μM Ube1 (E1), 5 μM 507 
gp78RING-Ube2g2, 2.5 μM Ub-GFP, and 5 μM Ub3 were incubated in 20 mM 508 
Hepes pH 7.4, 5 mM ATP, and 5 mM MgCl2 overnight at 37 °C. The Ub3Ub-GFP 509 
was then purified on Ni-NTA resin and a Superdex 200 gel filtration column 510 
before being concentrated with centrifugal filter units and flash frozen. 511 
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 512 
Polyubiquitylated substrate synthesis and purification 513 
Reactions were carried out with final concentrations of 10 μM Ub-GFP fusion 514 
protein, 1 μM E1, 20 μM gp78RING-Ube2g2, and 400 μM ubiquitin in 20 mM 515 
Hepes pH 7.4, 10 mM ATP, and 10 mM MgCl2 at 37 °C overnight. Ubiquitin was 516 
added progressively in small amounts over the first eight hours of the reaction. 517 
For FLAG-tagged substrate, 40 μM FLAG-Ubiquitin (Boston Biochem, 518 
Cambridge, MA, USA) was added in the first two hours. To purify ubiquitylated 519 
GFP from free ubiquitin chains, the reaction mixture was incubated with Ni-NTA 520 
resin, eluted with 300 mM imidazole, and run over a Superose 6 size exclusion 521 
column in 20 mM Hepes, pH 7.4, 250 mM KCl, 1 mM MgCl2, 1 mM TCEP and 522 
5% glycerol. Fractions were pooled into long, medium, and short chain length 523 
samples, concentrated with centrifugal filter units, and flash frozen. 524 
 525 
ATPase assays 526 
The ATPase assay protocol was modified from previously published methods 527 
(40). In an untreated microplate (#655101, Greiner Bio-One, Kremsmünster, 528 
Austria), 40 μL solutions containing 30 nM p97 hexamer, 150 nM adaptor, and/or 529 
150 nM substrate in ATPase assay buffer (25 mM Hepes pH 7.4, 100 mM KCl, 3 530 
mM MgCl2, 1 mM TCEP, 0.1 mg/mL ovalbumin) were preincubated at 37 °C for 531 
10 minutes. To this, 10 μL of a 1 mM ATP solution was added, and the reaction 532 
was incubated at 37 °C for 5 or 10 minutes. After cooling on ice for 30 seconds, 533 
50 μL of BIOMOL Green reagent (Enzo Life Sciences, Farmingdale, NY, USA) 534 
was added. Solutions were developed at room temperature for 30 minutes before 535 
being read at 600 nm. The amount of inorganic phosphate in each sample was 536 
calculated from a standard curve, and relative ATPase activity for a sample was 537 
calculated by normalizing its measurement to that of samples of WT p97 alone.  538 
 539 
Fluorescence unfolding assays 540 
Unless specified, all assays were carried out at 37 °C. Samples contained 25 nM 541 
GFP substrate, 75 nM p97 hexamer, 150 nM adaptor (UN, NSFL1C or UBXN7), 542 
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and/or 250 nM GroEL trap in unfolding assay buffer (25 mM Hepes pH 7.4, 100 543 
mM KCl, 5 mM MgCl2, 1 mM TCEP, 2 mM ATP). Control experiments indicated 544 
that the levels of p97, adaptor, and GroEL used were at or near saturation 545 
(Figure 2—figure supplement 4). Other nucleotides and p97 inhibitors were 546 
present at 2 mM and 10 μM, respectively, when indicated. Kinetic experiments 547 
were carried out on a Fluoro-Log 3 (Horiba Jobin Yvon, Edison, NJ, USA) with 548 
excitation at 488 nm and emission at 509 nm. Relative fluorescence was 549 
calculated by normalizing the fluorescence signal to that at time zero. Unfolding 550 
rates were calculated by fitting curves to an exponential decay model in Prism 551 
(GraphPad, San Diego, CA, USA). 552 
 553 
Binding assays 554 
Antibodies used for immunoprecipitation and western blotting are listed in Table 555 
S2. Samples containing 100 nM p97, 200 nM UN, 200 nM GFP substrate, and/or 556 
200 nM GroEL trap in binding assay buffer (25 mM Hepes pH 7.4, 100 mM KCl, 557 
3 mM MgCl2, 1 mM TCEP) in a volume of 200 μL were preincubated at 37 °C for 558 
15 minutes. Triton X-100 interfered with binding of substrate to GroEL trap, so 559 
0.01% Triton X-100 was included in all buffers only in reactions that did not 560 
contain GroEL. Nucleotides and inhibitors were present at 2 mM and 10 μM, 561 
respectively, where indicated. For IPs using Protein G magnetic beads (Bio-Rad 562 
Laboratories, Hercules, CA, USA), protein mixtures were incubated with 1 μL of 563 
antibody for 15 minutes at 37 °C prior to a 1 hour incubation with 25 μL of beads 564 
at room temperature. For FLAG IPs, reactions were incubated with 25 μL of anti-565 
FLAG resin (Sigma-Aldrich, St. Louis, MO, USA) for 15 minutes at room 566 
temperature. Following incubation, all beads were washed 3 times with 750 μL 567 
assay buffer before being boiled in 50 μL 2X SDS-PAGE loading dye. Samples 568 
were then analyzed by western blot. 569 
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 861 
 862 
Table and Figure Legends 863 
 864 
Table 1. Rates and extents of unfolding of UbLUb-UbLUb-GFP by p97 mutants. 865 
The rates and plateaus were calculated by fitting data to a single exponential 866 
decay, with the plateau representing the percent of fluorescence remaining at the 867 
end of the reaction. Unpaired t-tests comparing WT rates to those of p97-E305Q 868 
and p97-A232E yielded p-values of <0.0001 in both cases, indicating statistically 869 
significant differences. Sample size represents number of technical replicates, 870 
and values are shown ± S.D. 871 
 872 
Fig. 1. Substrate design and synthesis. (A) Preassembled, K48-linked Ub3 873 
chains containing a K48R mutation on the distal ubiquitin were ligated onto a 874 
non-cleavable linear His6-Ub-GFP fusion protein to produce pure Ub3Ub-GFP. (B) 875 
E1, E2, ubiquitin, and ATP were added to His6-Ub-GFP to elongate K48-linked 876 
ubiquitin chains of varying length on the ubiquitin fused to GFP. These resulting 877 
substrates were purified from free ubiquitin chains via Ni-NTA resin and crudely 878 
fractionated according to chain length via size exclusion chromatography to 879 
produce pools of “long,” “medium,” and “short” chain substrates (UbLUb-GFP, 880 
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UbMUb-GFP, and UbSUb-GFP, respectively). (C) To produce branched chains, Ub 881 
chains of varying length were enzymatically elongated on a di- or tri-ubiquitin 882 
linear fusion protein, Ub-Ub-GFP or Ub-Ub-Ub-GFP, similar to (B). (D) Size 883 
exclusion chromatogram and corresponding SDS-PAGE gel for the purification of 884 
substrate described in (B). 885 
 886 
Fig. 2. p97 unfolds Ub-GFP in a UN-dependent manner (A) SDS-PAGE 887 
analysis of GFP substrates with different Ub chain structures stained with 888 
Coomassie. (B) Upon addition of ATP, 75 nM p97, 150 nM UN, and 250 nM 889 
GroEL, 25 nM Ub-GFP and Ub3Ub-GFP did not appreciably lose fluorescence 890 
over time. However, Ub-GFP with “medium” or “long” K48-linked chains (UbMUb-891 
GFP and UbLUb-GFP) exhibited 26% and 32% loss of signal after 15 minutes, 892 
respectively.  Representative traces shown, n≥3. (C) Fluorescence of UbLUb-GFP 893 
did not change over time with the addition of p97, GroEL, or p97 plus GroEL. 894 
Upon addition of p97 plus UN, a small decrease in signal was observed, and this 895 
decrease was augmented with the addition of GroEL. Representative traces 896 
shown, n≥2. (D) UbLUb-GFP co-immunoprecipitated with GroEL only in the 897 
presence of p97 and UN. 898 
 899 
Fig. 3. Branched Ub chains are better p97 substrates. (A) SDS-PAGE 900 
analysis of Ub-GFP substrates stained with Coomassie. (B) Comparison of 901 
unfolding of substrates with one, two or three ubiquitins fused in tandem to GFP. 902 
Note that substrate with two linearly fused ubiquitins (e.g. UbMUb-UbMUb-GFP) 903 
was unfolded to a greater extent by p97 than substrate with a single linearly-904 
fused ubiquitin, even though aggregate ubiquitination for the latter substrate was 905 
at least as extensive or greater than the former. Adding an additional linearly-906 
fused ubiquitin (UbLUb-UbLUb-UbLUb–GFP) yielded no further improvement. 907 
Representative traces shown, n≥3. 908 
 909 
Fig. 4. ATPase activity of p97 is critical for and stimulated by substrate 910 
unfolding. (A) Fluorescence traces of UbLUb-UbLUb-GFP in the presence of p97, 911 
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UN, GroEL, and various nucleotides and p97 inhibitors. Unfolding was observed 912 
only in the presence of ATP. Representative traces shown, n≥2. (B) Unfolding of 913 
UbLUb-UbLUb-GFP by p97 ATPase mutants. p97-E305Q and p97-E578Q are 914 
deficient in D1 and D2 ATPase activity, respectively. p97-E305Q was able to 915 
unfold substrate whereas p97-E578Q was not. Representative traces shown, 916 
n≥3. (C) Substrate stimulates ATPase activity of p97 when UN is present. Both 917 
unanchored Ub chains and those linked to Ub-GFP yielded equivalent 918 
stimulation, while Ub-GFP and Ub3Ub-GFP did not stimulate. ATPase activity was 919 
measured with BioMol Green as described in Methods and was normalized to 920 
basal WT p97 activity. Error bars represent S.D. with n=4. (D) Effect of substrate 921 
plus UN on ATPase activity of D1 and D2 domain ATPase mutants. Addition of 922 
UbLUb-UbLUb-GFP plus UN slightly decreased ATPase activities of both D1 923 
mutant E305Q and D2 mutant E578Q. Error bars represent S.D. with n=4. 924 
 925 
Fig. 5. UN recruits ubiquitylated substrate to p97. (A) Association of substrate 926 
with p97 depends on UN. Reactions containing 100 nM p97, 200 nM UN, 200 nM 927 
UbLUb-UbLUb-GFP and/or 200 nM GroEL were immunoprecipitated using an anti-928 
p97 antibody and assessed by western blot. Substrate was pulled down with p97 929 
only in the presence of UN, and substrate enhanced the binding of UN to p97. 930 
Effects of substrate and UN on binding of GroEL to p97 could not be determined 931 
due to high background binding of GroEL to beads, antibody and/or p97. (B) UN 932 
binds directly to substrate and links it to p97. Samples prepared as in (A) were 933 
immunoprecipitated with an anti-GFP antibody. Substrate pulled down UN but 934 
only bound p97 in the presence of UN. (C) Bound nucleotide has only a modest 935 
effect on formation of a p97•UN•substrate ternary complex. Samples prepared as 936 
in (A) with various nucleotides and/or p97 inhibitors were immunoprecipitated by 937 
anti-FLAG resin, which bound the FLAG-tagged Ub on substrate. Binding of p97, 938 
but not UN, was reduced only in the ADP state. 939 
 940 
Fig. 6. IMBPFD mutant p97-A232E is a better unfoldase. (A) In the presence 941 
of UN and GroEL, p97-A232E catalyzed the loss of fluorescence of UbLUb-UbLUb-942 
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GFP faster than wild-type, suggesting it acts as an improved unfoldase. Rates 943 
are listed in Table 1 and the difference between WT and p97-A232E is 944 
statistically significant with p<0.0001. Representative traces shown, n ≥ 3. (B) 945 
p97-A232E shows accelerated ATPase rates in the presence of UN and 946 
substrate. The IBMPFD mutant also had both a higher baseline ATPase rate 947 
than WT (unpaired t-test, p<0.0001) and a higher ATPase activity in the presence 948 
of UN and substrate compared to WT (unpaired t-test, p=0.0003). ATPase 949 
activity was measured with BioMol Green as described in Methods was 950 
normalized to basal WT p97 activity. Error bars represent S.D. with n=4. (C) 951 
Addition of a 37.5 nM CB-5083 restores p97-A232E unfoldase activity to WT 952 
levels. Representative traces shown, n=2, and the difference between WT and 953 
p97-A232E rates is statistically significant (unpaired t-test, p=0.02). Independent 954 
preparations of proteins were used for panels (A) and (C). 955 
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Mutant Rate (s-1) Plateau (%) n 
WT 0.195 ± 0.007 33.3 ± 0.8 6 
E305Q 0.154 ± 0.005 36.5 ± 0.8 3 
E578Q N.D. N.D. 3 
A232E 0.274 ± 0.007 25.3 ± 0.4 3 
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